

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

PRODUCT INFORMATION



BO-264

Item No. 36611

CAS Registry No.: Formal Name:	2408648-20-2 N-[3-(4-methoxyphenyl)-5-isoxazolyl]-2- (4-morpholipyl) 4-pyrimidinamino			\sim
			н	
MF:	$C_{18}H_{19}N_5O_3$		ï	
FW:	353.4		~ _ Ń_	N N
Purity:	≥98%			$\gamma \gamma \gamma \gamma$
UV/Vis.:	λ _{max} : 252, 312 nm		$\langle $	
Supplied as:	A solid	/ \/	NO	
Storage:	-20°C			
Stability:	≥4 years			
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.				

Laboratory Procedures

BO-264 is supplied as a solid. A stock solution may be made by dissolving the BO-264 in the solvent of choice, which should be purged with an inert gas. BO-264 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BO-264 in these solvents is approximately 1 and 10 mg/ml, respectively.

Description

BO-264 is a transforming acidic coiled-coil containing protein 3 (TACC3) inhibitor.¹ It binds to TACC3 in thermal shift and drug affinity responsive target stability (DARTS) assays and inhibits the growth of JIMT-1, HCC1954, MDA-MB-231, MDA-MB-436, and CAL-51 cancer cells (IC₅₀s = 0.19, 0.16, 0.12, 0.13, and 0.36 µM, respectively). BO-264 is cytotoxic to RT4 cells that endogenously express TACC3-FGFR3 fusion proteins (IC₅₀ = 3.66 μ M). It induces mitotic arrest, apoptosis, and aberrant spindle formation and reduces centrosomal localization of TACC3 in JIMT-1 cells. BO-264 (25 mg/kg) reduces tumor volume and increases median survival in an EMT6 mouse xenograft model.

Reference

1. Akbulut, O., Lengerli, D., Saatci, O., et al. A highly potent TACC3 inhibitor as a novel anticancer drug candidate. Mol. Cancer Ther. 19(6), 1243-1254 (2020).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/20/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM